Clinical Trial Update: Phase 1/2a DTA-H19 in Patients With Unresectable Pancreatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2a trial of DTA-H19 in unresectable pancreatic cancer has completed with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Neoplasms

Drugs mentioned

• DTA-H19

Snippet

Sponsor: Anchiano Therapeutics Israel Ltd. | Conditions: Pancreatic Neoplasms | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2013-12-02